Search Login Register

Uveitis Summary

Description: Inflammation of part or all of the uvea, the middle (vascular) tunic of the eye, and commonly involving the other tunics (sclera and cornea, and the retina). (Dorland, 27th ed)

Also Known As: Uveitides

Networked: 4860 relevant articles (421 outcomes, 591 trials/studies) for this Disease

Key Drugs and Agents for Uveitis

Efficacy Chart >>
Drugs and Important Biological Agents (IBA) related to treatments:
  1. infliximab (Remicade) : 48 outcomes 23 studies in 138 results : FDA 2
  2. Cyclosporine (Ciclosporin) : 36 outcomes 22 studies in 180 results : FDA 20 Generic
  3. adalimumab (Humira) : 30 outcomes 19 studies in 74 results : FDA 2
  4. Tumor Necrosis Factor-alpha (Tumor Necrosis Factor) : 26 outcomes 23 studies in 181 results : IBA
  5. Adrenal Cortex Hormones (Corticosteroids) : 22 outcomes 15 studies in 236 results : IBA
  6. Steroids : 17 outcomes 5 studies in 155 results : IBA
  7. TNFR-Fc fusion protein (etanercept) : 14 outcomes 8 studies in 66 results : FDA 2
  8. Immunosuppressive Agents (Immunosuppressants) : 13 outcomes 4 studies in 77 results : IBA
  9. Methotrexate (Mexate) : 10 outcomes 12 studies in 72 results : FDA 8 Generic
  10. Retinaldehyde (Retinal) : 9 outcomes 34 studies in 411 results : IBA
Show All >>

Diseases Related to Uveitis

  1. Inflammation
  2. Macular Edema
  3. Juvenile Rheumatoid Arthritis (Juvenile Idiopathic Arthritis)
  4. Glaucoma
  5. Cataract (Cataracts)
Show All >>

Key Therapies for Uveitis

Efficacy Chart >>
  1. Vitrectomy : 16 outcomes 14 studies in 186 results
  2. Intravitreal Injections : 10 outcomes 12 studies in 84 results
  3. Injections : 9 outcomes 4 studies in 63 results
  4. Trabeculectomy (Trabeculoplasty) : 8 outcomes 4 studies in 47 results
  5. Aftercare (After-Treatment) : 8 outcomes 3 studies in 37 results
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.